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Background. For patients with human immunodeficiency virus (HIV) infection, structured treatment inter-
ruption (STI) is an attractive alternative strategy to continuous treatment, particularly in resource-restrained
settings, because it reduces both side effects and costs. One major concern, however, is the development of resistance
to antiretroviral drugs that can occur during multiple cycles of starting and stopping therapy.
Methods. HIV genotypic drug resistance was investigated in 20 HIV-infected Thai patients treated with highly
active antiretroviral therapy (HAART) and CD4 cell count–guided STI after dual nucleoside reverse-transcriptase
inhibitor (NRTI) treatment. Resistance was tested at the time of the switch from dual-NRTI treatment to HAART
and when HAART was stopped during the last interruption.
Results. After STI, one major drug-resistance mutation occurred (T215Y), and, in the 4 samples with pre-
existing major mutations (D67N [ ], K70R [ ], T215Y [ ], and T215I [ ]), the mutationsnp 2 np 2 np 2 np 1
disappeared. All mutations in the HIV protease gene were minor mutations already present, in most cases, before
STI was started, and their frequency was not increased through STI, whereas the frequency of reverse-transcriptase
gene mutations significantly decreased after the interruptions. After the 48-week study period, no patients had
virological failure. Long-term follow-up (108 weeks) showed 1 case of virological failure in the STI arm and 1 in
the continuous arm. No virological failure was seen in patients with major mutations.
Conclusions. Major HIV drug-resistance mutations were not induced through CD4 cell count–guided treat-
ment interruptions in HIV-infected patients successfully treated with HAART after dual-NRTI therapy.
The introduction of HAART has dramatically improved
the course of HIV infections [1, 2]. However, with
HAART being widely used, long-term toxicity occurs
[3, 4]. Although the therapy is cost-effective in some
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developed countries [5, 6], the costs of antiretroviral
drugs impose a major economic burden on countries
with limited resources like Thailand [7]. Structured
treatment interruption (STI) is, therefore, an attractive
alternative to continuous treatment, reducing both side
effects and costs. One major concern, however, is the
emergence of HIV with resistance to antiretroviral
drugs that can occur during multiple cycles of starting
and stopping therapy. Previous clinical trials investi-
gating STI in the treatment of well-controlled chronic
HIV infection did not demonstrate an increased oc-
currence of resistance [8–12]. However, new data dem-
onstrate the appearance of resistance during STI. A trial
HIV/AIDS • CID 2005:40 (1 March) • 729
with long-cycle STI, which is more similar to CD4 cell count–
guided treatment interruptions, and the use of efavirenz-based
HAART was stopped because of the occurrence of resistance
in 3 of 8 patients [13]. In another similar study with various
HAART regimens, resistance developed in 21.3% of patients
who receive STI [14]. In a trial with repeated cycles of STI,
M184V and L90M mutations could be detected in minor virus
populations at different times during the trial [15]. Further-
more, the week-on, week-off arm of a large treatment-inter-
ruption trial had to be discontinued because of virological fail-
ure [16]. Thus, the risk of emergence of resistance might have
been underestimated so far. In addition, these trials were per-
formed with patients who had no history of previous failure
to respond to antiretroviral therapy or in a mixed population,
restricting the population of patients who might profit from
STI. Previous results had shown that the week-on, week-off
strategy had to be stopped because of virological failure also
in patients previously treated with a dual nucleoside reverse-
transcriptase inhibitor (NRTI) regimen [17]. We therefore in-
vestigated genotyping resistance in patients previously treated
with dual-NRTI therapy who were being successfully treated
with HAART and were undergoing CD4 cell count–guided STI,
probably the most-promising interruption strategy for such
patients.
PATIENTS AND METHODS
STI for patients previously treated with dual-NRTI therapy fol-
lowed by HAART was investigated by the HIV Netherlands,
Australia, Thailand Research Collaboration (HIV-NAT) of the
Thai Red Cross AIDS Research Centre. An open-label, ran-
domized 3-arm study was conducted to evaluate and compare
the efficacy, safety, and tolerability of the following regimens:
(1) continuous treatment with saquinavir–soft gel capsule, 1600
mg once per day, plus ritonavir, 100 mg once a day, plus 2
NRTIs (either zidovudine and lamivudine or stavudine and
didanosine; (2) STI with the same regimen that was suspended
and restarted on alternating weeks of week on, week off; and
(3) STI with the same regimen that was suspended and restarted
on the basis of CD4 cell count–driven criteria (from study HIV-
NAT 001.4 [17]), in which therapy was stopped if the CD4 cell
count decreased to !350 cells/mL or to 30% of preinterruption
level, depending on the patient’s choice. Patients qualified for
the study if their last CD4 cell count was 1350 cells/mL and
their viral load had been !50 copies/mL for at least 6 months
prior to enrollment. The “week-on, week-off” arm had to be
discontinued because of virological failures at week 72 [17].
This strategy was not investigated further.
Ethics. The study was performed in accordance with the
approval of the ethics committee of Chulalongkorn University,
which conforms to the Helsinki Declaration of 1975, as revised
in 1983.
Participants. The participants were HIV-infected Thai pa-
tients who had participated in the HIV-NAT 001 trial series
that started in 1997, when they were treated with dual-NRTI
therapy that consisted of zidovudine and zalcitabine at either
the standard or half the standard dosage for 48 weeks, as de-
scribed in a previous publication [18]. Initial treatment was
followed by 3 years of saquinavir-based HAART [19]. If the
viral load remained undetectable (!50 copies/mL) and the CD4
cell count was 1350 cells/mL, a patient was enrolled in the study
after written informed consent had been obtained.
Procedures. During the 48-week observation period, pa-
tients randomized to either of the STI arms had an evaluation
every 2 months, and frozen plasma samples were obtained
for further analysis. To assess whether resistance was acquired
during multiple cycles of CD4 cell count–guided treatment
interruptions, HIV genotyping resistance testing was per-
formed on the first plasma sample with a viral load of 11000
copies/mL that was obtained after treatment was stopped dur-
ing the last cycle of treatment interruption, for the CD4-
guided arm. The “week-on, week-off” arm was not investi-
gated further, as this strategy showed too many virological
failures. To differentiate preexisting resistance from acquired
resistance, viral genotypic resistance testing was done on the
last plasma sample obtained before patients were switched
from dual-NRTI therapy to protease inhibitor–based HAART.
The methodology for HIV reverse-transcriptase genotyping
has been described elsewhere [20]. For the protease genotypic
resistance assay, the same methodology was used but with the
following primers: PI-1685 (5′-GGAATTTTCCTCAGAGCAG-
ACCAG-3′), PI-2209 (5′-TCTTCTGTCAATGGCCACTGTTT-
AAC-3′), and PI-2172 (5′-CCATTCCTGGCTTTAATGTTACT-
GGTAC-3′). We categorized major and minor mutations in
accordance with guidelines set by the International AIDS So-
ciety–US Drug Resistance Mutations Group [21].
Poststudy follow-up during STI totaled 108 weeks. For the
final 12 weeks, all patients were treated with continuous HAART.
Virological failure was defined as a viral load of 1500 copies/mL
at any time, for the continuous-treatment arm, and after 3
months of continuous HAART, for the STI arm.
Statistical analysis. Descriptive results are presented as
means SD, medians with interquartile range (IQR), and per-
centages. Inferential statistics using either parametric or non-
parametric tests were used, as appropriate for the data type.
The overall level of significance was set at ap0.05. To compare
means, medians, and proportions of investigated factors be-
tween groups with and groups without resistance, the Student’s
t test, Mann-Whitney U test, and x2 test were used. Fisher’s
exact test was used for small values for which the x2 test was
not applicable. Statistics were done using the SPSS software,
version 9.0 (SPSS).
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Table 1. Baseline characteristics of the 20 patients enrolled
in the CD4 cell count–guided structured treatment interruption
(STI) arm from whom plasma samples were available.
Characteristic Value
Demographic
Age, mean years SD 35.4 6.4
Sex
Females 9 (45)
Males 11 (55)
CDC HIV disease stage
CDC A 11 (55)
CDC B 8 (40)
CDC C 1 (5)
CD4 cell count, cells/mL (IQR)
Before ART 380 (150–563)
Before HAART 732 (550–872)
Before STI 766 (550–872)
Viral load
Median level before ART, log10 copies/mL (IQR) 4.8 (4.1–5.4)
Level !400 log10 copies/mL before HAART 7 (30.4)
HAART
No. of STI cycles, mean SD 1.65  0.67
NRTIs included
Zidovudine/lamivudine backbone 9 (45)
Stavudine/didanosine backbone 11 (55)
NOTE. Data are no. of patients (%), unless otherwise indicated. ART,
antiretroviral treatment; CDC, Centers for Disease Control and Protection;
NRTI, nucleoside reverse-transcriptase inhibitor.
RESULTS
Results for the primary end points of this study have been
presented elsewhere [17]. In summary, 74 NRTI-pretreated pa-
tients were included in the study, and continuous HAART was
compared with CD4 cell count–guided STI. “Week-on, week-
off” STI treatment was discontinued ahead of schedule, because
failures were unacceptably frequent (occuring in 12 [46%] of
26 patients) [17, 22]. At the time of virological failure, no HIV
with drug resistance was found in plasma samples from 3 pa-
tients, samples from 2 patients were not amplifiable, and, for
1 patient, no testing was done. Mutations in the HIV reverse-
transcriptase gene were found in samples from 3 patients (at
position 215 [ ] and positions 219, 210, 67, and 41np 3
[ for each]). Mutations in the HIV protease gene werenp 1
detected in samples from 4 patients (at position 63 [ ]np 3
and 82 [ ]). Of note, all patients had a viral load of !50np 1
copies/mL after reinitiating continuous HAART. The “week-
on, week-off” strategy was unreliable and thus not investigated
further. Twenty-three patients were treated with CD4-guided
STI, and 25 patients were treated with continuous HAART. The
observational period was 48 weeks, and follow-up continued
for 108 weeks. After 108 weeks (96 weeks of STI and 12 weeks
of continuous treatment), 1 case of virological failure, defined
as a viral load 1500 copies/mL, occured after 3 months of
continuous treatment, in a patient with nonadherence in the
STI group [22]. Another failure occurred in the continuous
treatment group at week 96; no results of resistance testing
were available for this patient.
Frozen plasma samples obtained before HAART were avail-
able from 20 (87%) of the patients, and samples obtained after
STI were available from 20 (87%) of the patients. Baseline
characteristics of these patients are shown in table 1. Of note,
only 30% of patients had a copies/mL before switch-VL ! 400
ing from dual-NRTI (zidovudine/zalcitabine) treatment to
HAART. The NRTI regimen was changed from zidovudine/
zalcitabine to zidovudine/lamivudine for 9 patients and to sta-
vudine/didanosine for 11 patients. The female-to-male sex ratio
was balanced, and the mean age (SD) was 35.4 6.4 years.
Most patients (55%) were asymptomatic before starting anti-
retroviral therapy. Depending on their reaction to STI, the pa-
tients underwent 1–3 (mean, 1.65) treatment interruptions dur-
ing the 48-week observation period. Resistance testing was
performed at a median of 32 days (IQR, 28–63.5 days) after
treatment was stopped during the last treatment interruption
within the 48-week observation period.
Table 2 shows the results of HIV genotyping before HAART
and after CD4 cell count–guided STI. Genotyping could be
done on 11 samples obtained before HAART, and 9 samples
could not be amplified. Three of these 9 samples had a viral
load of !400 copies/mL, and, in 6 other samples, RNA deg-
radation had occurred. In 11 samples obtained before the switch
from dual-NRTI treatement to HAART, mutations were found
in 4 (36%), and no mutation was present in 7 (64%). In 17
samples obtained after CD4 cell count–guided STI, resistance
mutations were found 9 (53%). Three of these 17 samples could
not be amplified, possibly because of mutations at the primer
site. HIV mutations present before the start of protease inhib-
itor–based HAART and detected after STI are shown in figure
1 and table 2. Major mutations were found in 4 (36%) of 11
samples obtained before HAART and in 1 (6%) of 17 samples
obtained after STI ( , by Fisher’s exact test). ThePp .062
matched pair comparison showed that minor mutations in the
HIV protease gene that were present before HAART were also
found after STI. Minor mutations emerged in HIV from 4
samples, and, in HIV from 1 sample, 1 mutation was lost. New
mutations were acquired by HIV in 2 samples, and 2 samples
obtained before HAART could not be amplified. Preexisting
mutations in the HIV reverse-transcriptase gene disappeared
after STI. In 2 patients with this HIV mutation pattern, the
virus reverted to wild type, whereas, in 2 others, secondary
mutations which do not lead to drug resistance were present
after the treatment interruption. Only 1 major mutation
(T215Y) occurred after STI, in a patient with HIV that did not
have genotoypic resistance before HAART. As shown in figure
2, the frequency of mutations in the HIV reverse-transcriptase
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Table 2. Drug-resistance profile of HIV in patients who received structered treatment interruption (STI), as
determined before HAART and after the last cycle of STI.
NRTIs included
in HAART
Before HAART After last cycle of STI
No. of
STI cycles
CD4
cell count,
cells/mL
Viral load,
copies/mL Mutation(s)a
CD4
cell count,
cells/mL
Viral load,
copies/mL Mutation(s)a
D4T/DDI 113 !400 NA 554 569 None 2
AZT/3TC 835 2083 None 348 212,000 T215Y 1
D4T/DDI 872 2829 NA 872 59,600 NA 1
AZT/3TC 426 1591 NA 530 2250 NA 1
D4T/DDI 530 2339 None 384 18,100 None 2
AZT/3TC 581 488 None 533 40,400 V77I 2
AZT/3TC 419 !400 NA 360 61,400 NA 1
AZT/3TC 851 15,714 NA 746 80,700 K20R 2
D4T/DDI 956 1538 None 1183 19,800 None 2
D4T/DDI 1028 1077 NA 672 7070 None 2
D4T/DDI 599 1949 L10I 642 16,200 L10I, L63P 2
D4T/DDI 766 8378 NA 630 19,300 None 2
AZT/3TC 550 11,175 D67N, K70R,
T215Y
351 9510 None 2
AZT/3TC 698 !400 NA 576 2870 L63P 3
D4T/DDI 1316 2216 T215Y, L63P 607 4320 L63P 3
AZT/3TC 814 2024 L10V, K20R,
L63P
814 57,700 K20R, L63P 1
D4T/DDI 804 1309 T215F 804 214,000 None 1
D4T/DDI 664 !400 L63P 664 27,400 L63P 1
AZT/3TC 608 31,796 D67N, K70R,
T215I, L10V,
L63S
783 69,500 K103T, L10V,
L63S
1
D4T/DDI 1082 1747 NA 1084 23,200 None 1
NOTE. AZT, zidovudine; DDI, didanosine; D4T, stavudine; NA, HIV not able to be amplified; 3TC, lamivudine.
a Mutations in bold are in the reverse-transcriptase gene, and mutations in italics are in the protease gene.
gene was significantly reduced, from 72% before HAART to
12% after STI ( , by Fisher’s exact test). The frequencyP ! .01
of mutations in the protease gene did not significantly change
(72% vs. 65% after STI).
During the 48-week observation period, the same HAART
regimen remained effective in suppressing the viral load in all
patients who had to restart therapy for at least 3 months, in
accordance with the protocol criteria. Eighteen patients who
reinitiated HAART achieved a viral load of !500 copies/mL
after 3 months of continuous therapy. The median viral load
rebound after STI was 4.6 log10 copies/mL (IQR, 3.9–4.9) in
patients with drug-resistant HIV and 4.3 log10 copies/mL (IQR,
3.9–4.3) in patients without drug-resistant HIV. After posttrial
follow-up of 108 weeks, 1 patient had a viral load of 1500
copies/mL 3 months after reinitiating HAART, which qualified
as virological failure. This failure occurred at week 72 because
the patient did not adhere to reinitiated HAART. The patient
demonstrated no major HIV mutations after STI and was dis-
continued from the study. At week 108, all patients had received
3 months of continuous HAART. All but the patient mentioned
above had a viral load of !400 copies/mL [22]. The factors
believed to predict the occurrence of HIV drug-resistance mu-
tations after STI—presence of resistance before HAART, viral
load rebound, CD4 cell count at the time of initiation of STI,
number of STI cycles, CD4 cell count before antiretroviral ther-
apy, CD4 cell count before HAART, viral load before HAART,
sex, and the NRTIs included in the HAART—were investigated
without significant results.
DISCUSSION
CD4 cell count–guided STI was tested in 23 HIV-infected Thai
patients who had previously been treated with dual-NRTI ther-
apy. Samples from 20 patients were available for HIV genotypic
resistance testing. The patients were switched to HAART for 3
years and had a viral load of !50 copies/mL before enrollment.
Before HAART, antiretroviral–associated major HIV reverse-
transcriptase mutations were found in 4 (36%) of 11 samples,
and minor mutations were found in 5 (45%) of 11 samples.
After CD4 cell count–guided treatment, only 1 (6%) of 17 had
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Figure 1. HIV drug-resistance mutations detected in plasma samples
obtained from patients before HAART (before) and after structured treat-
ment interruption (after). NA, not able to be amplified.
Figure 2. Frequency of mutations in the reverse-transcriptase (RT) and
protease (PR) genes, defined as the total number of mutations divided
by the number of amplified plasma samples, before HAART (before) and
after structured treatment interruption (after).
major mutations, and minor mutations were found in 8 (47%)
of 17 samples. No virological failure was seen in patients with
major HIV mutations after 108 weeks of follow-up.
HIV with drug resistance is a major concern in STI and has
been shown to occur in clinical trials investigating structured
interruptions of HAART [13, 15, 16, 23]. On the other hand,
it also has been shown that interruption of HAART can convert
a resistant virus population to wild-type virus [24–27]. Al-
though this strategy has been harmful in the patients receiving
salvage therapy [28], the situation may be different in im-
munologically intact patients infected with HIV resistant to
NRTIs but treated successfully with HAART. Indeed, major HIV
mutations present after dual-NRTI therapy and before HAART
had disappeared after STI. Seventy percent of our patients had
a detectable viral load of 1 400 copies/mL after dual-NRTI
therapy. Despite having undetectable viral load after HAART,
they can be considered a population at risk for resistance de-
velopment after STI. However, a major HIV mutation was
found in only 1 patient after STI, and this did not lead to
virological failure during a follow-up period of 108 weeks. To
our knowledge, this study is the first investigation of STI done
exclusively in HIV-infected patients with viral supression who
are treated with HAART after dual-NRTI therapy.
In this CD4 cell count–guided treatment-interruption trial,
HIV mutations were frequently observed after STI in patients
previously treated with dual-NRTI therapy before HAART.
However, only 1 of these mutations (T215Y) was a major mu-
tation. HIV from 8 patients displayed 1 or 2 secondary mu-
tations, which alone do not result in resistance to antiretrovirals.
They probably represent naturally occurring polymorphisms
rather than drug-selected mutations. Indeed, the minor HIV
protease gene mutations seen after STI were nearly all present
before initiation of HAART. Major mutations seen after STI
involved the reverse-transcriptase gene, whereas minor muta-
tions involved polymorphic positions coding for the protease
gene. In our study, positions 10, 20, 63, and 77 were involved.
Although these mutations do not cause significant drug resis-
tance by themselves, some of them contribute to drug resistance
when present together with other protease mutations [29, 30].
Whether further HIV mutations will be acquired and thus lead
to clinical drug resistance after additional cycles of STI cannot
be determined from the data available at present. But none of
the patients, except for the one who did not adhere to HAART,
developed virological failure by week 108 of follow-up. One
other case of virological failure occurred in the continuous
treatment arm [22]. Deeks et al. [31] have shown that durable
suppression of the HIV virus population may be achieved with
a combination regimen containing only 1 fully active agent.
Patients infected with HIV that developed major mutations still
had at least 1, and usually 2, drugs that were still active against
the strain, which could explain why even patients with resistant
HIV responded well to reinitiation of HAART after treatment
interruption. How sustainable viral suppression will be remains
to be seen. Nevertheless, after 108 weeks of follow-up and with
only 1 treatment failure, CD4 cell count-guided STI appears
to be safe in this patient population. Accordingly, all patients
with major HIV mutations in the “week-on, week-off” arm
whose treatment failed had a viral load of !50 copies/mL after
reinitiation of HAART. Using a univariate model, we found no
factors predicting the development of HIV mutations. In ac-
cordance with a study performed in a very similar group of
patients, multidrug resistance against NRTIs was frequently
seen in patients predominantly infected with HIV subtype A/
E for whom NRTI treatment failed [20]. In our study, presence
of preexisting mutations was not associated with development
of resistance after STI. However, when mutations were present
before initiation of HAART, we observed either reversion to
wild-type virus or substitution of these mutations with minor
mutations during STI. Interestingly, the frequency of reverse-
transcriptase gene mutations significantly decreased after STI,
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and there was a trend toward a reduction in the number of
preexisting major mutations in the HIV reverse-transcriptase
gene after STI. Whether these mutations truly disappeared or
whether we just measured overgrowth of wild-type virus is
difficult to determine. The time from the stopping HAART to
the performance of genotyping was 32 days, and a previous
study has shown that, within the first 30 days, most reverse-
transcriptase mutations remain [25]. Although we cannot con-
clude from our data that CD4 cell count–guided STI is ben-
eficial for such patients, we did not find any harmful effects of
STI on the virological outcome.
The study has some limitations. The strength of the results
and conclusions is somewhat diminished by the limited sample
size. Because of RNA degradation, 6 samples could not be
amplified. Another 3 samples could not be amplified due to
probable mutations at the primer site. During the last treat-
ment-interruption cycle, half of our patients had genotyping
performed 130 days after stopping HAART (median, 32 days).
It is possible that mutated viruses were not detected because
of the relative increase in the number of wild-type viruses.
However, Miller et al. [25] showed that mutations in the re-
verse-transcriptase gene remain largely unchanged 30 days after
treatment interruption. Moreover, all major HIV mutations in
our study population were mutations in the reverse-transcrip-
tase gene. The observed decrease in major mutations may also
have been due to random effects caused by small sample size
and nonamplification of samples, rather than STI.
Nevertheless, the study offers an interesting insight into the
effect of STI on patients who have received suboptimal antiret-
roviral therapy before HAART, and it is the first investigation
that exclusively studied patients previously treated with dual-
NRTI therapy. The long clinical follow-up of 108 weeks strength-
ens many of the conclusions and also supports the further use
of CD4 cell count–guided STI in controlled conditions for pa-
tients with preexisting major HIV mutations. This is relevant,
since STI may become an important treatment strategy in re-
source-limited places like Thailand, where many patients have
previously been treated with dual-NRTI therapy and thus harbor
HIV with major mutations in the reverse-transcriptase gene [20].
In conclusion, major HIV mutations were not induced
through CD4 cell count–guided treatment interruptions in
HIV-infected patients successfully treated with HAART after
dual-NRTI therapy. However, the power of this trial is limited,
and a cautious follow-up is necessary. The prevalence of in-
fection with HIV with major mutations conferring drug resis-
tance by themselves decreased from 36% of patients before CD4
cell count–guided STI to 6% after STI. Also, the mutations did
not correlate with virological response to HAART so far, and
the presence of preexisting mutations after dual-NRTI therapy
did not negatively influence the virological outcome of STI.
These findings only apply for the chosen CD4 cell count–guided
treatment interruption strategy and cannot be extrapolated to
other interruption strategies.
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